Previous 10 | Next 10 |
Which of the healthcare producers of Diagnostic Solutions is now a better buy to help build your portfolio’s near-term capital value? Near-term only, repetition provides long term. Here find out what the best-informed, big-$ investors now think is likely to happen (good and bad...
The American Medical Association Approves a New Category I CPT® Code for the HelioLiver™ Test PR Newswire The approval of a CPT code establishes a reimbursement pathway for increased access to HelioLiver, a simple blood test to detect hepatocellular carcino...
Greenblatt believes that a company with the ability to invest in its business and receive a strong return on that investment is usually a “good” company. Greenblatt measures the strength of a business by examining its return on capital, which he defines as operating prof...
The company has raked in well over $1B of cash from its epic Covid testing ramp up, apart from a host of contacts and putting the company on the map. It is spending some of that on acquisitions and a massive stock buyback that is yet to commence. However, this is counterbalanced b...
Image source: The Motley Fool. Fulgent Genetics, Inc. (NASDAQ: FLGT) Q1 2022 Earnings Call May 03, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Fulgent Genetics, Inc. (FLGT) Q1 2022 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q1 2022 Earnings Conference Call May 3, 2022, 04:30 PM ET Company Participants Nicole Borsje - IR Ming Hsieh - CEO Brandon Perthuis - Chief Commercial Officer Larry Weiss - Chief Medical Officer Paul Kim - CFO Conference Call Participants Kevin DeGeeter - Oppenhe...
Fulgent Genetics (NASDAQ:FLGT) raised its 2022 revenue guidance to $660M (from $600M) but also lowered its full-year non-GAAP net income outlook to $6 per share (from $7). The genetic testing services company saw its net income in Q1 2022 decline 23% to ~154M ($4.93 per diluted share) compare...
The following slide deck was published by Fulgent Genetics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Fulgent Genetics, Inc. 2022 Q1 - Results - Earnings Call Presentation
Fulgent Genetics press release (NASDAQ:FLGT): Q1 Non-GAAP EPS of $5.08 beats by $1.22. Revenue of $320.27M beats by $19.77M. Outlook: Q2: Total Revenue of approximately $125 million; Core Revenue of approximately $40 million, representing growth of 78% year-over-year. Consensus EPS ...
Revenue totals $320.3 million Core Revenue excluding COVID-19 NGS testing grows 59% year-over-year to $25.1 million Raises full year revenue outlook to $660 million from previously announced $600 million Raises full year core revenue outlook to $180 million from previously...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results be...
2024-07-01 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...